FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205369318> ?p ?o ?g. }

• W4205369318 endingPage "626" @default.
• W4205369318 startingPage "625" @default.
• W4205369318 abstract "The most recent SARS-CoV-2 variant of concern to emerge has been named omicron.1WHOClassification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. Statement 26 November, 2021.https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concernDate accessed: December 6, 2021Google Scholar Its immune evasion potential was predicted by genomic data and has been preliminarily confirmed by observations of an increased incidence of reinfections and breakthrough infections.2Pulliam JRC van Schalkwyk C Govender N et al.Increased risk of SARS-CoV-2 reinfection associated with emergence of the omicron variant in South Africa.medRxiv. 2021; (published online Dec 2.) (preprint).https://doi.org/10.1101/2021.11.11.21266068Google Scholar This has triggered calls to intensify vaccination programmes including provision of vaccine booster doses.3Dolgin E Omicron is supercharging the COVID vaccine booster debate.https://www.nature.com/articles/d41586-021-03592-2Date: Dec 2, 2021Date accessed: December 6, 2021Google Scholar A group of German visitors who had received three doses of SARS-CoV-2 vaccines, including at least two doses of an mRNA vaccine, experienced breakthrough infections with omicron between late November and early December, 2021, while in Cape Town, South Africa. The group consisted of five White women and two White men with an average age of 27·7 years (range 25–39) and a mean body-mass index of 22·2 kg/m2 (range 17·9–29·4), with no relevant medical history. Four of the individuals were participating in clinical elective training at different hospitals in Cape Town, whereas the others were on vacation. The individuals were members of two unlinked social groups and participated in regular social life in Cape Town, in compliance with applicable COVID-19 protocols. Upon arrival during the first half of November, 2021, each individual tested negative for SARS-CoV-2 by PCR and provided records of complete vaccination, including booster or third, doses administered via intramuscular injection using homologous (n=5) and heterologous (n=2) vaccination courses (appendix p 3).4European Medicines AgencyEMA and ECDC recommendations on heterologous vaccination courses against COVID-19.https://www.ema.europa.eu/en/news/ema-ecdc-recommendations-heterologous-vaccination-courses-against-covid-19Date: Dec 7, 2021Date accessed: December 9, 2021Google Scholar Six individuals were fully vaccinated with BNT162b2 (Comirnaty, Pfizer–BioNTech, Mainz, Germany), five of whom received a third (booster) dose of BNT162b2 in October or early November, 2021. One individual had received a full dose of CX-024414 (Spikevax, Moderna, Cambridge, MA, USA) in early October, 2021; this was not in line with the European Medicines Agency recommendations at that time, which suggested a half dose to boost healthy individuals.5European Medicines AgencySpikevax: EMA recommendation on booster.https://www.ema.europa.eu/en/news/spikevax-ema-recommendation-boosterDate: Oct 25, 2021Date accessed: December 9, 2021Google Scholar The seventh individual received an initial dose of ChAdOx1-S (Vaxzevria, AstraZeneca, Cambridge, UK), followed by a dose of BNT162b2 for completion of primary immunisation, and a booster dose of the same vaccine. Except for the CX-024414 booster, all vaccinations were in accordance with European recommendations.4European Medicines AgencyEMA and ECDC recommendations on heterologous vaccination courses against COVID-19.https://www.ema.europa.eu/en/news/ema-ecdc-recommendations-heterologous-vaccination-courses-against-covid-19Date: Dec 7, 2021Date accessed: December 9, 2021Google Scholar, 5European Medicines AgencySpikevax: EMA recommendation on booster.https://www.ema.europa.eu/en/news/spikevax-ema-recommendation-boosterDate: Oct 25, 2021Date accessed: December 9, 2021Google Scholar The early timepoints of some individuals' primary and booster vaccinations were due to their occupation in the medical field. Nobody reported a history of SARS-CoV-2 infection. During a marked increase in incidence of SARS-CoV-2 infections in the Western Cape province, these individuals observed onset of respiratory symptoms between Nov 30 and Dec 2, 2021. SARS-CoV-2 infections were diagnosed by ISO 15189-accredited diagnostic laboratories using molecular assays approved by the national regulator. The investigation was approved by the Health Research Ethics Committees of Stellenbosch University (C21/12/004_COVID-19) and the University of Cape Town (279/2021) and all participants provided informed consent. We obtained swab and serum samples 2–4 days after onset of symptoms. Futher details of how samples were processed are provided in the appendix (p 2). All patients were placed in domestic isolation and used a daily symptom diary to document the course of disease during the observation period of 21 days. Illness was classified as mild (n=4) or moderate (n=3; shortness of breath) according to National Institutes of Health COVID-19 Treatment Guidelines. Two individuals were asymptomatic by the end of the observation period (day 21). Blood oxygenation levels (SPO2) remained in the normal range (>94%) without exception and none of the patients required hospitalisation. Prevalence of symptoms over time is provided in the appendix (p 4). All seven individuals were infected with omicron (PANGO lineage B.1.1.529, Nextstrain clade 21K). Viral loads ranged from 4·07 to 8·22 (mean 6·38) log10 viral RNA copies per mL of swab eluate. Anti-spike antibody levels ranged from 15 000 arbitrary units (AU) per mL to more than 40 000 AU/mL, with a mean of approximately 22 000 AU/mL of serum (appendix p 3). Robust CD4 and CD8 T-cell responses to SARS-CoV-2 spike, nucleocapsid, and membrane proteins were detected in six of the participants tested after a minimum of 2 weeks after onset of symptoms (appendix p 5), at frequencies of 0·011–0·192% for CD4+ and 0·004–0·079% for CD8+ T cells. These were the first documented breakthrough infections with the omicron variant in fully vaccinated individuals after receipt of booster vaccine doses. Some of these individuals had received heterologous vaccine doses, in line with emerging global practice. Booster doses were administered 21–37 weeks after the second vaccine doses, and breakthrough infections occurred 22–59 days thereafter. At the onset of their breakthrough infections, all individuals had high levels of viral spike protein binding antibodies, similar to levels reported 4 weeks following second vaccine doses6Grupel D Gazit S Schreiber L et al.Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination.Vaccine. 2021; 39: 5337-5340Crossref PubMed Scopus (9) Google Scholar and as expected after receipt of booster vaccine doses.7Demonbreun AR Sancilio A Vaught LA et al.Antibody titers before and after booster doses of SARS-CoV-2 mRNA vaccines in healthy adults.medRxiv. 2021; (published online Nov 21.) (preprint).https://doi.org/10.1101/2021.11.19.21266555Google Scholar Viral RNA loads in omicron variant infections have yet to be reported. It remains unknown whether the viral loads observed in our group are different from those in unvaccinated, or differently vaccinated, individuals. During wild-type SARS-CoV-2 infection, an average viral RNA load of 5·83 log10 viral RNA copies per swab was found in samples taken up to day after onset of symptoms,8Wölfel R Corman VM Guggemos W et al.Virological assessment of hospitalized patients with COVID-2019.Nature. 2020; 581: 465-469Crossref PubMed Scopus (3566) Google Scholar with a maximum of 8·85 log10 viral RNA copies per swab. In this group of individuals, an average of 6·38 log10 viral RNA copies per mL of eluted swab was detected, with the highest viral load (8·22 log10) detected on day 4 after onset of symptoms. This suggests that the individuals were infectious, in keeping with the occurrence of infection clusters sparing none of the members of the two groups. Specific T-cell responses were detected in all participants tested at least 2 weeks after symptom onset, in the range reported after vaccination,9Keeton R Richardson SI Moyo-Gwete T et al.Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner.Cell Host Microbe. 2021; 29 (19.e5): 1611Summary Full Text Full Text PDF PubMed Scopus (21) Google Scholar with additional T-cell responses to the viral nucleocapsid and membrane proteins. The mild to moderate course of illness suggests that full vaccination followed by a booster dose still provides good protection against severe disease caused by omicron. However, we cannot exclude long-term sequelae of COVID-19. Furthermore, our findings are limited to a low number of individuals in relatively young and otherwise healthy individuals (n=7). This case series adds further evidence that, as predicted, omicron is able to evade immunity induced by mRNA vaccines in vivo. South Africa only recently introduced booster vaccinations for individuals immunised with two doses of BNT162b2, so the presence of this group from Germany presented a unique opportunity to study omicron breakthrough infections in individuals with mRNA vaccine boosters. In-vitro data suggest lower titres of neutralising antibodies against omicron compared with other SARS-CoV-2 lineages following BNT162b2 vaccination but increased titres after a third dose,10Cele S Jackson L Khan K et al.Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.Nature. 2021; (published online Dec 23.)https://doi.org/10.1038/s41586-021-04387-1Crossref Scopus (108) Google Scholar, 11Wilhelm A Widera M Grikscheit K et al.Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies.medRxiv. 2021; (published online Dec 13.) (preprint).https://doi.org/10.1101/2021.12.07.21267432Google Scholar, 12PfizerPfizer and BioNTech provide update on omicron variant. Press release.https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-omicron-variantDate: Dec 8, 2021Date accessed: December 9, 2021Google Scholar supporting calls for booster doses while the omicron variant appears to be spreading globally. Our study, however, demonstrates insufficient prevention of symptomatic infection in otherwise healthy individuals who had received three doses of COVID-19 mRNA vaccines. These findings support the need for updated vaccines to provide better protection against symptomatic infection with omicron13Devlin H Kollewe J BioNTech says it could tweak Covid vaccine in 100 days if needed.https://www.theguardian.com/society/2021/nov/26/biontech-says-it-could-tweak-covid-vaccine-in-100-days-if-neededDate: Nov 26, 2021Date accessed: December 7, 2021Google Scholar and emphasise that non-pharmaceutical measures should be maintained. Encouragingly, early data from South Africa suggest maintained if reduced effectiveness of the BNT162b2 vaccine against hospital admission.14Collie S Champion J Moultrie H Bekker LG Gray G Effectiveness of BNT162b2 vaccine against omicron variant in South Africa.N Engl J Med. 2021; (published online Dec 29.)https://doi.org/10.1056/NEJMc2119270Crossref PubMed Scopus (82) Google Scholar For National Institutes of Health COVID-19 Treatment Guidelines see https://www.covid19treatmentguidelines.nih.govFor SARS-CoV-2 infections in the Western Cape province see https://coronavirus.westerncape.gov.za/covid-19-dashboard For National Institutes of Health COVID-19 Treatment Guidelines see https://www.covid19treatmentguidelines.nih.gov For SARS-CoV-2 infections in the Western Cape province see https://coronavirus.westerncape.gov.za/covid-19-dashboard CK and CKM contributed equally. We declare no competing interests. This online publication has been corrected. The corrected version first appeared at thelancet.com on February 10, 2022 This online publication has been corrected. The corrected version first appeared at thelancet.com on February 10, 2022 Download .pdf (.33 MB) Help with pdf files Supplementary appendix Department of ErrorKuhlmann C, Mayer CK, Claassen M, et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet 2022; 399: 625-26—In this Correspondence, the affiliation details of WA Burgers, R Keeton, and C Riou have been corrected to Institute of Infectious Disease and Molecular Medicine (WAB, RK, CR) and Wellcome Centre for Infectious Diseases Research in Africa (CR), University of Cape Town, Observatory, Cape Town, South Africa. These corrections have been made to the online version as of Feb 10, 2021, and the printed version is correct. Full-Text PDF" @default.
• W4205369318 created "2022-01-25" @default.
• W4205369318 creator A5001133659 @default.
• W4205369318 creator A5020926690 @default.
• W4205369318 creator A5028725144 @default.
• W4205369318 creator A5036323567 @default.
• W4205369318 creator A5038022169 @default.
• W4205369318 creator A5068714653 @default.
• W4205369318 creator A5078919067 @default.
• W4205369318 creator A5080047959 @default.
• W4205369318 creator A5089023238 @default.
• W4205369318 creator A5089704709 @default.
• W4205369318 creator A5090617518 @default.
• W4205369318 date "2022-02-01" @default.
• W4205369318 modified "2023-10-18" @default.
• W4205369318 title "Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose" @default.
• W4205369318 cites W3013893137 @default.
• W4205369318 cites W3188544165 @default.
• W4205369318 cites W3207910965 @default.
• W4205369318 cites W3215756704 @default.
• W4205369318 cites W4220673385 @default.
• W4205369318 cites W4220987557 @default.
• W4205369318 cites W4225729728 @default.
• W4205369318 doi "https://doi.org/10.1016/s0140-6736(22)00090-3" @default.
• W4205369318 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35063123" @default.
• W4205369318 hasPublicationYear "2022" @default.
• W4205369318 type Work @default.
• W4205369318 citedByCount "245" @default.
• W4205369318 countsByYear W42053693182021 @default.
• W4205369318 countsByYear W42053693182022 @default.
• W4205369318 countsByYear W42053693182023 @default.
• W4205369318 crossrefType "journal-article" @default.
• W4205369318 hasAuthorship W4205369318A5001133659 @default.
• W4205369318 hasAuthorship W4205369318A5020926690 @default.
• W4205369318 hasAuthorship W4205369318A5028725144 @default.
• W4205369318 hasAuthorship W4205369318A5036323567 @default.
• W4205369318 hasAuthorship W4205369318A5038022169 @default.
• W4205369318 hasAuthorship W4205369318A5068714653 @default.
• W4205369318 hasAuthorship W4205369318A5078919067 @default.
• W4205369318 hasAuthorship W4205369318A5080047959 @default.
• W4205369318 hasAuthorship W4205369318A5089023238 @default.
• W4205369318 hasAuthorship W4205369318A5089704709 @default.
• W4205369318 hasAuthorship W4205369318A5090617518 @default.
• W4205369318 hasBestOaLocation W42053693181 @default.
• W4205369318 hasConcept C116675565 @default.
• W4205369318 hasConcept C121332964 @default.
• W4205369318 hasConcept C12590561 @default.
• W4205369318 hasConcept C126322002 @default.
• W4205369318 hasConcept C1276947 @default.
• W4205369318 hasConcept C159047783 @default.
• W4205369318 hasConcept C203165030 @default.
• W4205369318 hasConcept C2522874641 @default.
• W4205369318 hasConcept C2779134260 @default.
• W4205369318 hasConcept C3006700255 @default.
• W4205369318 hasConcept C3007834351 @default.
• W4205369318 hasConcept C3008058167 @default.
• W4205369318 hasConcept C32611913 @default.
• W4205369318 hasConcept C524204448 @default.
• W4205369318 hasConcept C71924100 @default.
• W4205369318 hasConceptScore W4205369318C116675565 @default.
• W4205369318 hasConceptScore W4205369318C121332964 @default.
• W4205369318 hasConceptScore W4205369318C12590561 @default.
• W4205369318 hasConceptScore W4205369318C126322002 @default.
• W4205369318 hasConceptScore W4205369318C1276947 @default.
• W4205369318 hasConceptScore W4205369318C159047783 @default.
• W4205369318 hasConceptScore W4205369318C203165030 @default.
• W4205369318 hasConceptScore W4205369318C2522874641 @default.
• W4205369318 hasConceptScore W4205369318C2779134260 @default.
• W4205369318 hasConceptScore W4205369318C3006700255 @default.
• W4205369318 hasConceptScore W4205369318C3007834351 @default.
• W4205369318 hasConceptScore W4205369318C3008058167 @default.
• W4205369318 hasConceptScore W4205369318C32611913 @default.
• W4205369318 hasConceptScore W4205369318C524204448 @default.
• W4205369318 hasConceptScore W4205369318C71924100 @default.
• W4205369318 hasFunder F4320320672 @default.
• W4205369318 hasFunder F4320320673 @default.
• W4205369318 hasIssue "10325" @default.
• W4205369318 hasLocation W42053693181 @default.
• W4205369318 hasLocation W42053693182 @default.
• W4205369318 hasLocation W42053693183 @default.
• W4205369318 hasOpenAccess W4205369318 @default.
• W4205369318 hasPrimaryLocation W42053693181 @default.
• W4205369318 hasRelatedWork W3021484935 @default.
• W4205369318 hasRelatedWork W3032377983 @default.
• W4205369318 hasRelatedWork W3110327078 @default.
• W4205369318 hasRelatedWork W3178186717 @default.
• W4205369318 hasRelatedWork W4200432472 @default.
• W4205369318 hasRelatedWork W4206654052 @default.
• W4205369318 hasRelatedWork W4210401150 @default.
• W4205369318 hasRelatedWork W4283825065 @default.
• W4205369318 hasRelatedWork W4287374796 @default.
• W4205369318 hasRelatedWork W4292099921 @default.
• W4205369318 hasVolume "399" @default.
• W4205369318 isParatext "false" @default.
• W4205369318 isRetracted "false" @default.
• W4205369318 workType "article" @default.